Rehmann Capital Advisory Group’s Charles River Laboratories CRL Stock Holding History

Rehmann Capital Advisory Group’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-766	Closed	-$218K	–	513
2022 Q1	$218K	Sell	766 -22	-3%	-$6.78K	0.02%	485
2021 Q4	$297K	Buy	788 +27	+4%	+$10.5K	0.03%	438
2021 Q3	$314K	Buy	761 +1	+0.1%	+$415	0.03%	425
2021 Q2	$283K	Buy	760 +10	+1%	+$3.34K	0.03%	444
2021 Q1	$217K	Sell	750 -139	-16%	-$38.6K	0.02%	480
2020 Q4	$222K	Buy	889 +3	+0.3%	+$714	0.03%	448
2020 Q3	$201K	Buy	+886	New	+$184K	0.03%	410
2019 Q3	$81.5K	Buy	616 +221	+56%	+$29.6K	0.01%	502
2019 Q2	$56K	Sell	395 -1	-0.3%	-$136	0.01%	791
2019 Q1	$57.5K	Sell	396 -36	-8%	-$4.73K	0.01%	769
2018 Q4	$48.9K	Buy	432 +34	+9%	+$4.26K	0.01%	594
2018 Q3	$53.5K	Sell	398 -4	-1%	-$494	0.01%	767
2018 Q2	$45.1K	Buy	402 +300	+294%	+$32.4K	0.01%	819
2018 Q1	$11K	Buy	+102	New	+$11K	﹤0.01%	1273

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rehmann Capital Advisory Group's CRL Position: Q2 2022 in Review

Rehmann Capital Advisory Group sold out of Charles River Laboratories (CRL) in Q2 2022, closing a stake of 766 shares — an estimated $218K sold.

Rehmann Capital Advisory Group first reported a position in CRL in Q1 2018 and held it in 14 quarters. The position peaked at $314K in Q3 2021. 627 funds tracked by Wall St. Rank hold CRL as of Q2 2022.

Rehmann Capital Advisory Group reported no remaining Charles River Laboratories position as of Q2 2022 after selling out during the quarter.
Rehmann Capital Advisory Group sold 766 Charles River Laboratories shares in Q2 2022, an estimated $218K.
Rehmann Capital Advisory Group first reported a position in Charles River Laboratories in Q1 2018 and held it in 14 quarters.
Rehmann Capital Advisory Group's Charles River Laboratories position peaked at $314K in Q3 2021.
627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2022.

Based on Rehmann Capital Advisory Group's 13F filing for Q2 2022, filed 12 Aug 2022.